Bodhi Tree Biotechnology INC (BDTB) — SEC Filings

Overview

Bodhi Tree Biotechnology INC (BDTB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 29, 2025: Bodhi Tree Biotechnology Inc. (BDTB), incorporated on December 12, 2023, is an early-stage consulting company specializing in plant-based menu design, recipe development, and vegetarian diet consulting services. The company reported no public market for its common stock as of its most recently compl

Sentiment Summary

Across 7 filings, the sentiment breakdown is: 2 bearish, 5 neutral. The dominant filing sentiment for Bodhi Tree Biotechnology INC is neutral.

Filing Type Overview

Bodhi Tree Biotechnology INC (BDTB) has filed 1 10-K, 2 10-Q, 1 10-Q/A, 1 8-K, 1 S-1/A, 1 S-1 with the SEC between Feb 2025 to Dec 2025.

Recent Filings (7)

• Bodhi Tree Biotech: Early-Stage, Capital-Hungry, No Public Market — 10-K · Dec 29, 2025 Risk: high
  Bodhi Tree Biotechnology Inc. (BDTB), incorporated on December 12, 2023, is an early-stage consulting company specializing in plant-based menu design, recipe de
• Bodhi Tree Biotech Plunges to $139K Loss Amid Soaring Expenses — 10-Q · Aug 12, 2025 Risk: high
  Bodhi Tree Biotechnology Inc. (BDTB) reported a significant net loss of $138,979 for the nine months ended June 30, 2025, a stark contrast to the net income of
• Bodhi Tree Biotech Amends 10-Q, Confirms Smaller Reporting Status — 10-Q/A · Jul 28, 2025 Risk: low
  Bodhi Tree Biotechnology Inc. filed a 10-Q/A for the quarter ended March 31, 2025, indicating an amendment to its previous quarterly report. The filing confirms
• Bodhi Tree Biotechnology Files 8-K — 8-K · Jun 6, 2025 Risk: low
  Bodhi Tree Biotechnology Inc. filed an 8-K on June 5, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the even
• Bodhi Tree Biotech Files 10-Q for Q2 2025 — 10-Q · May 20, 2025 Risk: low
  Bodhi Tree Biotechnology Inc. filed its 10-Q for the period ending March 31, 2025. The filing covers the second quarter of their fiscal year, which began on Oct
• Bodhi Tree Biotechnology Files IPO Amendment — S-1/A · Feb 21, 2025 Risk: medium
  Bodhi Tree Biotechnology Inc. filed an S-1/A amendment on February 21, 2025, for its initial public offering. The company, incorporated in Delaware, is based in
• Bodhi Tree Biotechnology Files S-1 for Public Offering — S-1 · Feb 4, 2025 Risk: medium
  Bodhi Tree Biotechnology Inc. filed an S-1 registration statement on February 3, 2025, for an unspecified amount of securities to be offered from time to time.

Risk Profile

Risk Assessment: Of BDTB's 7 recent filings, 2 were flagged as high-risk, 2 as medium-risk, and 3 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Bodhi Tree Biotechnology INC's most recent 10-K filing (Dec 29, 2025):

• Revenue: $0
• Net Income: $0
• EPS: $0
• Debt-to-Equity: N/A
• Cash Position: $0
• Operating Margin: N/A
• Total Assets: $0
• Total Debt: $0

Key Executives

• Xiaohang Wang
• Juan Ye
• Danville, CA
• Cassi Olson, Esq.
• Cassi Olson

Industry Context

Bodhi Tree Biotechnology Inc. operates in the burgeoning plant-based food and wellness sector, driven by increasing consumer interest in flexitarian, vegetarian, and organic lifestyles. The market is characterized by a growing demand for healthier, sustainably sourced options and innovative recipe development. However, the industry also faces competition from established food companies and a proliferation of smaller, specialized businesses.

Top Tags

Biotechnology (3) · biotechnology (2) · ipo (2) · Consulting (1) · Plant-Based (1) · Early-Stage (1) · High-Risk (1) · Micro-Cap (1) · Illiquid (1) · 10-Q Filing (1)

Key Numbers

• Shares of Common Stock outstanding: 25,441,042 — As of December 29, 2025, indicating the current equity structure.
• Public market for common stock: 0 — No public market existed as of the last business day of the most recently completed second fiscal quarter, highlighting illiquidity.
• Registered trademarks: 2 — Approved on August 5, 2025, and September 30, 2025, representing the company's limited intellectual property.
• Full-time employees (non-executive): 0 — Operations are carried out by management, indicating minimal operational infrastructure.
• Incorporation date: 2023-12-12 — Highlights the company's very limited operating history.
• Net Loss: $138,979 — For the nine months ended June 30, 2025, compared to $9,612 net income in 2024.
• Revenue: $5,000 — For the nine months ended June 30, 2025, down from $15,000 in 2024.
• General and Administrative Expenses: $141,931 — For the nine months ended June 30, 2025, significantly up from $5,388 in 2024.
• Cash: $119,516 — As of June 30, 2025, a decrease from $259,570 as of September 30, 2024.
• Accumulated Deficit: $200,932 — As of June 30, 2025, an increase from $61,953 as of September 30, 2024.
• Basic and Diluted Loss Per Share: $0.01 — For the nine months ended June 30, 2025.
• Common Shares Outstanding: 25,441,042 — As of August 12, 2025.
• Quarter End Date: 2025-03-31 — The period covered by the 10-Q/A filing.
• Filing Date: 2025-07-28 — The date the 10-Q/A was filed with the SEC.
• Amendment Number: 1 — This is Amendment No. 1 to the original 10-Q.

Frequently Asked Questions